CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
CVI.00122-07v1
14/7/875    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gomes-Solecki, M. J. C.
Right arrow Articles by Dattwyler, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gomes-Solecki, M. J. C.
Right arrow Articles by Dattwyler, R. J.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, July 2007, p. 875-879, Vol. 14, No. 7
1071-412X/07/$08.00+0     doi:10.1128/CVI.00122-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Epitope Length, Genospecies Dependency, and Serum Panel Effect in the IR6 Enzyme-Linked Immunosorbent Assay for Detection of Antibodies to Borrelia burgdorferi{triangledown}

Maria J. C. Gomes-Solecki,1,3 Luciana Meirelles,1 John Glass,2 and Raymond J. Dattwyler1,3*

New York Medical College, Valhalla, New York 10595,1 Brookhaven National Laboratory, Upton, New York 11973,2 Biopeptides Corp., Valhalla, New York 105953

Received 16 March 2007/ Returned for modification 26 April 2007/ Accepted 18 May 2007

In the absence of erythema migrans, the basis for diagnosis of Lyme disease is the demonstration of an antibody response against Borrelia burgdorferi in an appropriate clinical setting. The C6 enzyme-linked immunosorbent assay, based on the IR6 region of VlsE, has become widely used in both the United States and Europe. We mapped the antigenic epitopes of IR6 to a shorter sequence that is equivalent in sensitivity and specificity to the full-length IR6 25-residue peptide. In addition, we observed significant differences in sensitivity between serum panels (60 to 100%), indicating that the selection of the serum panels can shape the apparent overall sensitivity of the assay. Contrary to prior reports, the assay sensitivity is greater when the IR6 peptide is derived from the sequence of the same infecting Borrelia genospecies. Using our North American panels and the two panels obtained from European Lyme disease patients, we determined that the IR6 assay that is based on a single genospecies of Borrelia spp. is not optimal for use as a universal diagnostic assay for Lyme disease.

* Corresponding author. Mailing address: New York Medical College, BSB Room 308, Valhalla, NY 10595. Fax: (914) 594-4922. E-mail: raymond_dattwyler{at}nymc.edu

{triangledown} Published ahead of print on 30 May 2007.

Clinical and Vaccine Immunology, July 2007, p. 875-879, Vol. 14, No. 7
1071-412X/07/$08.00+0     doi:10.1128/CVI.00122-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.